Joel Greenblatt Ultragenyx Pharmaceutical Inc. Transaction History

Gotham Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$31.73 - $49.19 $237,276 - $367,842	7,478 New	7,478 $357,000
Q2 2023 Aug 14, 2023	SELL	$37.35 - $52.15 $113,506 - $158,483	-3,039 Reduced 16.11%	15,822 $729,000
Q1 2023 May 15, 2023	BUY	$36.99 - $48.71 $361,725 - $476,335	9,779 Added 107.67%	18,861 $756,000
Q4 2022 Feb 14, 2023	BUY	$33.72 - $46.33 $107,094 - $147,144	3,176 Added 53.78%	9,082 $420,000
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $236,003 - $390,622	5,906 New	5,906 $245,000
Q1 2021 May 17, 2021	SELL	$106.9 - $167.73 $165,267 - $259,310	-1,546 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$84.4 - $177.39 $130,482 - $274,244	1,546 New	1,546 $214,000
Q2 2019 Aug 14, 2019	SELL	$54.93 - $74.36 $250,590 - $339,230	-4,562 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$39.87 - $69.36 $181,886 - $316,420	4,562 New	4,562 $316,000

325

85.5M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.14B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.